Veranova, a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors, today announced a strategic investment to establish state-of-the-art bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus.

This expansion will enable Veranova to provide a more comprehensive suite of services to partners developing antibody-drug conjugates (ADCs) and other bioconjugates, and builds on the Devens facility’s extensive experience in the development and clinical and commercial manufacture of ADC linker-payloads. Combined with a previously announced expansion of high-potent synthesis capacity in Devens, this will represent a more than $50 million investment into the site’s capabilities for ADCs and other bioconjugates and will create up to 70 new jobs. The new capacity is planned to come online in June 2026.

The investment also addresses increasing demand for strong U.S.-based biomanufacturing capabilities and will help U.S.-based customers secure domestic supply chains for critical drug substances.

The bioconjugation expansion will include new process and analytical development laboratories, grade C cleanroom space, development and cGMP equipment and instrumentation, and supporting infrastructure. These capabilities will support up to kilogram-scale manufacturing of potent and non-potent bioconjugates.

“We continue to see ADCs and other conjugated molecules as a key growth area as our customers look to develop more targeted therapies,” said Mike Riley, CEO of Veranova. “This investment will build on our core capabilities in complex chemistry, analytics and linker-payload synthesis, and leverage our strategically located cGMP infrastructure to provide a differentiated solution to our customers.”